- Home
- SGHT vs ALT Comparison
SGHT vs ALT Comparison
Compare SGHT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGHT | ALT |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.5M | 415.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGHT | ALT |
|---|---|---|
| Price | $5.35 | $4.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $8.23 | ★ $16.00 |
| AVG Volume (30 Days) | 255.9K | ★ 5.3M |
| Earning Date | 03-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $76,052,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.03 | $2.90 |
| 52 Week High | $9.24 | $7.73 |
Technical Indicators
Market Signals| Indicator | SGHT | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 46.13 |
| Support Level | $5.46 | $4.47 |
| Resistance Level | $6.15 | $5.75 |
| Average True Range (ATR) | 0.38 | 0.44 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 20.59 | 7.94 |
Price Performance
Historical ComparisonAbout SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.